Souhaitez-vous accéder aux communiqués récents ?

Applied Biologics completes enrollment in the CAMPX RCT evaluating XWRAP® for chronic diabetic foot ulcers across 23 SerenaGroup sites.

XWRAP showed statistically significant wound closure improvement vs. standard of care alone in the CAMPX RCT — 31% vs. 18% (ITT, p=0.023).

WINNIPEG, Manitoba, May 13, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today its participation in the World Council of Enterostomal...

Cellution Biologics publishes first peer-reviewed clinical data showing improved healing outcomes for non-healing diabetic foot ulcers.

Austin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, the global Diabetic Ulcer Treatment Market was valued at USD 8.22 billion in 2023 and is projected to reach USD 14.35 billion by...

Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds100% diabetic wound closure in ≤ 12 weeksPreclinical sustained antibiofilm activity for a minimum of 7 days WINNIPEG, Manitoba, Nov....

RedDress today announced that ActiGraft Pro has been added to the Wound Care Advantage (WCA) Formulary after a comprehensive evaluation.

Patients treated with ActiGraft Pro from RedDress are more than twice as likely to heal compared with those receiving standard of care per a new study.

Lewes, Delaware, July 31, 2024 (GLOBE NEWSWIRE) -- The Global Hyperbaric Oxygen Therapy Market Size is projected to grow at a CAGR of 6.30% from 2024 to 2031, according to a new report published by...

DiaSafe™, IR-MED’s second product, is being developed to provide safe, real-time optical readings of biomarkers to detect the early presence of diabetic foot ulcers with high accuracyThe most common...